Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems. The global market for highly potent active pharmaceutical ingredients (HPAPIs) has been growing ...
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three ...
The development of successful ADCs involves careful selection of drug, antibody, and linker, as well as choosing the right attachment chemistry to link the cytotoxic to the antibody. Antibody-drug ...
As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and ...
Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...
Antibody-drug conjugates (ADCs) are formed by covalent biochemical conjugation of monoclonal antibodies (mAb) with payload drugs through small molecular linkers. They are regarded as an emerging class ...
The use of antibodies as delivery vehicles for drug payloads in antibody–drug conjugates (ADCs) and simplified variants of traditional antibody models (i.e., nanobodies) are particularly versatile ...
The use of antibodies as delivery vehicles for drug payloads in antibody–drug conjugates (ADCs) and simplified variants of traditional antibody models (i.e., nanobodies) are particularly versatile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback